药明康德2024年度报告

WuXi AppTec Co., Ltd.* 2359 2024 245637384671117123126128130133264 20251222025122 20251222025122 20251222025122 88135 288 33191910 201 81–38 8 1283 1151509 118 28824 333 A 50147 188 H 33 1617 A603259H02359 47917 www.wuxiapptec.cn/zh-hk/ 20245.2%493.147.0% CRDMOCRDMO202510-15% 2025317 1. A. 39,241.42.7%9,352.612.5% CRDMO 20246,0005,5001,0002024493.147.0% —20166.424.1% —250.27.7%52.314.4%70.73.5%19.311.4% 22024WuXi ATUWuXi ATU 3 39,241.420232.7%5.2% (1)WuXi Chemistry 290.511.2% —RResearch20244610%CRDMO2024R D366 —DMDevelopment and ManufacturingD&M178.76.4%CDMO20241,1872024D&M3,3777280III360II2,865IIII202425202420254,000kL20242026202452027 —TIDESTIDES58.070.1%2024TIDES103.9%TIDES D&M15%22%202441,000L2025100,000L (2)WuXi Testing 56.7 —38.68.0%13.0%2024(NMPA)(OECD) GLP(PMDA)mRNA40% —CROSMO18.12.8%SMO15.4%2024CRO291SMO73SMO255 (3)WuXi Biology 25.4 —202429.9%18.7%202428% —29020211,400—202420% 202510%–15%415–430CRDMO 20252025 16,016.120232.2%40.8%0.2 (1)WuXi Chemistry 13,272.21.8 (2)WuXi Testing 1,843.95.3 (3)WuXi Biology 955.42.7 202312311,350.320241231804.4(1)WuXi XDC CaymanInc.20231,097.6(2)2024WuXi XDC Cayman Inc.567.7 20231231240.920241231334.3 2023123167.420241231115.6 2023123149.620241231110.4 20241231948.4 2023123135.120241231252.1WuXi XDC CaymanInc. 20231231193.620241231268.6 2024123111,986.8202312315.2%2023202412312122.1% 202412315,098.02023123125.2% 202412313,832.7202312312.7%2024530A 2024123121,240.22023123118,151.933.1%20.0%16.4%10.6%19.9% (1) 202412314,238.11,278.62,959.52,993.31,244.82,196.2300.02,041.9 (2) 2024123122.1 (3) 20241231 (4) 2024123126.4%2023123124.6%2024 B. (i)(ii)(iii) D. 202412311,233.98 (1)(2)(3) 12.2 372.1 20241231 Genesis Medtech Group LimitedGenesis Genesis202412311,647.52.1% Genesis20241231Genesis1,5482,00050% iKang Healthcare GroupiKang iKang20241231488.40.6% iKang2019120241231iKang5715518iKang200800 20241231289.80.4% 20241231170.30.2% (RDC)FIC/BICBR-02CDEFDAINDIITRDCRDC 20241231132.20.2% 80FDA 202412315% E. (1) (2) CRDMOWuXi TIDES(TFF)CMCPROTAC (3) 20 202420254,000kL202441,000L2025100,000L20242026202452027 (4) 2020246,000 4,0006315203410 (5) F. (1)2019 AA 2024312019A12019A83,629AA0.0033%0.0028%A202437202431 20243182019A122019A101,376AA0.0040%0.0034%A20243222024318 (2)2019 20192019202362720245253111,690,93338.622023619 202463030720191,659,424AAA(T)(T+1)A(T+2)31,5092024712024729 (3)2023 20246122023202320232024625109.8974202451020245272024612 (4)2022H2022 292,04020222022382022H0.0754%0.0100%20241112024624 (5)2023H 202310302023HH2023H15,467,500H 20234242023103020234272023531 (6)2024H2024H10H 2024H20246122023202420242024H 20249242024HH10H27,478,428H0.94%H2024H2024383 2024429202492420245102024612 (7)500,000,0002025 2024107500,000,000500,000,00020241021 494,400,00020241022 20241082024102120241022 (8) 2024202420232025317 A. 20247Frost & Sullivan20232,60620283,5926.6% Frost & Sullivan202349.2%202858.2%CDMO20231,36920282,38811.8% B. (1)CRDMO(2)CRDMO(3) C. 2025CRDMO (1) (2) (3) 2025 (4) PROTAC (5) (1)(2)(3)(4) (6) (7) 2024(UNGC)SBTiPSCIMSCICDPEcoVadis D. (1) (2) (3) CRO/CDMO (4) (5) 1182025119 (6) (7) (8) (9) (10) 12525 3 5819932000PharmacopeiaInc.20002269.HK 5520VertexPharmaceuticals Inc.2008 62198319851988198919891990Jurid Bremsbrag GmbH1996199819982000Biogen Inc.BIIB.NASDAQ20002007Tanox, Inc.TNOX.NASDAQ20072616.HK1228.HKAmbrx Biopharma Inc.AMAM.NYSE Carnegie Mellon University 5619971999Strategic Decisions Group19992001IntraBiotics2001200620072010PFE.NYSE20112014AZR.NYSE2014 55199119931993199519951998199820002000 51199820002000200820082011201151060.HK 57199620082008200920092013201310201412269.HK 561520072021WuXi PharmaTech (Cayman) Inc.WXPactera Technology International Ltd.PACTXueda Education GroupXUEWuXi Biologics (Cayman) Inc.(2269.HK) 1990719944 7130201920062018(300642.SZ) 198211988819928 472010(603610.SH)(601595.SH)(603728.SH) 199972002320105 61200481987198919942004PestalozziBaker & McKenzie 198471987719933 49201882025120153202112200442014126699 19976 55202512219999200782007920141220151Lupin Capital3690.HKCIH 1992719995 582017319911995GTI1996200520052023 602020820002019 53201732001 5020221120214201519972002 (EFLP) 6119901995BMS19951997VionPharma19982004Eli Lilly and Company20042024 3620136201642016520189201810 ————— C1 20241231C.2.1 C3 20241231 1252520241231 12 2025122 1.2.20251222025122 202512220251163.09D 20163232017317 C.2.1 20241231 3.13 1— 525 B.2.2 20241231 20241231 1. AB 102 1821 41–5051–6061–7071–80 525 5412 156 471 43113 (1) (2) (3) (4) (a) (b) (c) (d) (5) (6) (7) (8) 20241231 4 • ••17•••• •••••••• • • • • • • ••••• ••••••• HAH A.2.1 20241231 (i)(ii)(iii)(iv)(v) (i)(ii)(iii)(iv)(v)(vi)(vii)(viii) (i)(ii)(iii)(iv)(v)(vi) ••••• • • • •202412311 20241231 202412316.83.9 20241231 — 202412313.2915 •••10%••• 9010% 3%